The stock of RepliCel Life Sciences Inc (CVE:RP) is a huge mover today! About 26,106 shares traded hands or 6.90% up from the average. RepliCel Life Sciences Inc (CVE:RP) has risen 6.00% since October 5, 2016 and is uptrending. It has outperformed by 4.91% the S&P500.
The move comes after 7 months positive chart setup for the $6.26 million company. It was reported on Nov, 4 by Barchart.com. We have $1.69 PT which if reached, will make CVE:RP worth $4.88 million more.
More important recent RepliCel Life Sciences Inc (CVE:RP) news were published by: Marketwired.com which released: “RepliCel Life Sciences Share Consolidation Approved” on August 09, 2016, also Marketwired.com published article titled: “RepliCel Life Sciences Amends Terms of Private Placement”, Marketwired.com published: “RepliCel Life Sciences Announces Completion of the Final Injection in Its …” on August 11, 2016. More interesting news about RepliCel Life Sciences Inc (CVE:RP) was released by: Marketwired.com and their article: “RepliCel Life Sciences Announces Closing of Private Placement” with publication date: October 31, 2016.
RepliCel Life Sciences Inc. is a regenerative medicine firm focused on developing autologous cell therapies that treat functional cellular deficits. The company has a market cap of $6.26 million. The Company’s product pipeline includes RCT-01-Tendon Repair, RCS-01-Skin Rejuvenation, RCH-01-Hair Regeneration and RCI-02-Dermal Injector. It currently has negative earnings. RCT-01 is an autologous cell treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle sheath to treat chronic tendinosis caused by acute and chronic tensile overuse.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.